glp 1 houston New GLP-1 drug will be made in Houston-Led Trial Finds Oral GLP‑1
Description
Just two weeks later, on 1 April 2026, the FDA approved Foundayo, Eli Lillys brand name for orforglipron, making it the first small-molecule, non-peptide oral GLP-1 receptor agonist approved for chronic weight management
Anyone looking for a quick fix
This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management
The 2023 New England Journal of Medicine publication described a randomized, double-blind, placebo-controlled Phase 2 trial in adults with obesity or overweight with at least one related condition
